Revenue segments as reported by the company.

Software products and services

Drug discovery

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales and marketing

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Schrodinger 

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Schrodinger reports robust revenue growth and eyes strategic expansion

Schrodinger delivered strong financial performance in 2022, driven by revenue growth in software and drug discovery segments.
The company's innovative pipeline advancements and focus on neuroscience therapeutics position it well for future growth.
While facing challenges in operating expenses and revenue projections, Schrodinger has opportunities for expansion through partnerships and customer growth.
Capitalizing on existing strengths and addressing challenges will be key for Schrodinger to sustain its growth trajectory and competitive edge.

Schrodinger (SDGR) reports robust Q1 performance and growth opportunities

Schrodinger (SDGR) had a strong Q1 2023, with revenue growth driven by software and drug discovery collaborations.
The company's balance sheet strengthened, but challenges exist with smaller biopharma revenue mix and customer acquisition.
Opportunities lie in capitalizing on existing customer loyalty, potential revenue growth, and continued investments in technology.
Overall, Schrodinger is well-positioned to leverage its strengths and address challenges to drive future growth.

Schrodinger meets revenue expectations, focuses on AI-driven drug discovery

Schrodinger's Q2 2023 earnings call highlighted solid revenue performance, ongoing software revenue discussions, and investments in R&D for platform development. The company showcased strengths in innovative drug discovery methods, progress on proprietary programs, and FDA clearances. Challenges include revenue fluctuations and uncertainties in revenue projections, while opportunities lie in expanding software contracts and leveraging AI for efficiency.

Schrodinger reports solid Q3 growth amidst expense challenges and opportunities

Schrodinger's Q3 performance showed revenue growth driven by software and drug discovery segments, despite increased expenses.
The company's focus on operational efficiency and proprietary programs positions it well for future growth and market expansion.
While facing challenges in managing expenses and uncertainties in partner priorities, Schrodinger remains committed to innovation and value creation.
Opportunities lie in scaling up software usage, evaluating collaboration programs, and leveraging customer interest for revenue growth.

Schrodinger reports strong revenue growth and strategic collaborations in 2023

Schrodinger's financial performance in 2023 reflects growth in total revenue and software revenue, driven by customer expansions and program advancements.
The company's strengths lie in its strategic focus on global biopharma companies, collaborations for AI tools, and the trend towards hosted contracts.
Challenges include forecasting revenue growth, decision-making on program advancement, and factors influencing software revenue dynamics.
Opportunities exist in the increased demand for computational tools, ongoing discussions for software adoption, and the validation of the platform through collaborations.

Schrodinger reports Q1 revenue growth amidst challenges and collaboration opportunities

Schrodinger's Q1 2024 performance reflects revenue growth driven by software revenue, though challenges in China and decreased gross margin were noted.
The company's strengths lie in regained rights to key inhibitors, promising pipeline advancements, and potential growth in ACV and collaboration opportunities.
While facing challenges in profitability and R&D expenses, Schrodinger is well-positioned to capitalize on opportunities in collaborations, funding, and drug development.
Overall, Schrodinger's strategic focus on innovation, partnerships, and pipeline advancement sets the stage for future growth and market expansion.

Schrodinger reports solid Q2 results, eyes strategic growth opportunities

Schrodinger's Q2 performance reflects steady revenue growth and margin improvement, despite operational challenges.
Strategic partnerships, acquisitions, and innovative solutions position Schrodinger for future expansion and market leadership.
Efforts to control expenses, drive revenue growth, and leverage market opportunities will be crucial for Schrodinger's long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the quarter ended on September 30, 2023. “Schrodinger had an excellent third quarter marked by strong revenue growth and significant pipeline progress. More of our software customers are increasing the scale of their use of our technology, and we remain very confident about the outlook for.

Schrödinger Reports Third Quarter 2023 Financial Results

Mexico Fund

Vir Biotechnology

When investors think of Bill Gates stocks, they inevitably come up with Microsoft (NASDAQ: MSFT ), the software company he co-founded with Paul Allen in 1975 in Albuquerque. However, as Gates has spent less time around Microsoft's business, the billionaire has significantly diversified his investment portfolio.

3 Bill Gates Stocks to Buy for Billionaire-Like Returns

Schrödinger has a physics-based platform that helps accelerate drug discovery. The company sells its software to other businesses and has its own drug pipeline.

This Artificial Intelligence (AI) Stock Is Powering the Biotech Revolution: Should You Invest?

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will report third quarter 2023 financial results on November 1, 2023.

Schrödinger to Announce Third Quarter 2023 Financial Results on November 1

This company uses AI to improve drug discovery for all of the 20 biggest biopharmaceutical companies. Even the most pessimistic analyst thinks the stock could jump nearly 32% over the next 12 months.

Why Wall Street Thinks This Artificial Intelligence (AI) Stock Could Skyrocket 140% Over the Next 12 Months

C3.ai

Upstart Holdings

I don't think there is any debate on the point that Nvidia (NASDAQ: NVDA ) has established itself as the godfather of AI. As growth accelerates for Nvidia in a big addressable global market, the company's stock has skyrocketed by 220% year-to-date (YTD).

3 Artificial Intelligence Stocks That Could Outperform the ‘Godfather of AI'

ASML Hld

Alphabet

iCAD

ServiceNow

Super Micro Computer

The transformative power of artificial intelligence ( AI ) — with regards to drug makers and banks to oil companies to every firm that carries out intensive sales activities — is widely known. Yet in spite of all of these points, it appears that the Street — which has been much more focused on a one percentage point change in bond rates lately than the revolutionary power of AI — is giving very few AI stocks the credit they deserve.

7 Trailblazing AI Stocks to Buy on Any Weakness

Schrödinger is a leading AI drug discovery company with a comprehensive platform used by researchers and scientists worldwide. The company's flagship product, Maestro, integrates various proprietary software tools for molecular modeling and simulation. SDGR has experienced significant growth and has established itself as the industry standard in the AI revolution in healthcare.

Schrodinger: Leading The AI Healthcare Revolution

Schrödinger discovers new medicines using advanced technologies like AI. It has already helped a collaborator bring a pair of drugs to market.

This AI Biotech Stock Is Already Profitable. Should You Buy It?

SoundHound AI Inc

Symbotic Inc

SoundHound AI continues to score wins in the auto and restaurant industries with its voice AI technology. Schrodinger is changing how drug discovery is done.

3 Artificial Intelligence (AI) Stocks That Could Soar More Than Nvidia, According to Wall Street

Allison Transmission Hlds

See two of the featured stocks from this month's model portfolios.

The Good And Bad: Allison Transmission & Schrodinger Inc.

ExScientia Ltd

Recursion Pharmaceuticals

Schrödinger uses AI to drive revenue for both of its segments. Recursion got a big boost from computer chipmaker Nvidia.

3 AI Drug Discovery Stocks to Watch

Gates has a long history with this pioneer of AI drug discovery. The Gates Foundation Trust currently owns more than 11% of the company.

Here's Bill Gates' Top Artificial Intelligence Stock Other Than Microsoft -- and Wall Street Thinks It Can Soar Nearly 70% Over the Next 12 Months

Schrodinger's stock has performed well this year due to AI hype and strength in its drug discovery business. While the company appears attractively valued from a long-term perspective, the tight financing environment is currently a headwind. Investor sentiment is likely to ebb and flow along with broader interest in AI, creating downside risk in the near term.

Schrodinger: More Than An AI Bubble Stock

DraftKings

General Electric

Microsoft

NVIDIA

Rivian Automotive

Tesla

There's no foolproof method for making money in the stock market, and, in my view, no one should rely on any one technique for picking stocks. After all, using multiple criteria — including analyzing fundamentals, checking charts, and identifying macro trends — should increase one's chances of success.

7 Stocks the Big Money Is Buying Now

Bristol-Myers

Artificial intelligence is changing the drug-discovery process by making it much faster and cheaper.  Traditionally, most biotech stock drug candidates fail.

Biotech Breakthroughs: 3 Companies on the Cusp of Major Discoveries

Many investors, including a significant number of very wealthy individuals and institutions, are becoming enthralled with AI stocks. According to Goldman Sachs (NYSE: GS ), up to $200 billion could be poured into the technology by 2025.

3 AI Stocks Billionaires Are Loading Up On

Second-quarter revenue was down 9% year over year. Schrödinger increased revenue guidance for software revenue but decreased it for drug discovery.

Why Shares of Schrödinger Are Falling Thursday

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.62 per share a year ago.

Schrodinger, Inc. (SDGR) Reports Q2 Loss, Misses Revenue Estimates

Schrödinger, Inc. (NASDAQ:SDGR ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Jaren Madden - SVP, IR & Corporate Affairs Ramy Farid - CEO Geoff Porges - CFO Karen Akinsanya - President R&D, Therapeutics Conference Call Participants Michael Yee - Jefferies David Lebowitz - Citigroup Evan Seigerman - BMO Capital Markets Vikram Purohit - Morgan Stanley Matt Hewitt - Craig-Hallum Gaurav Goparaju - Berenberg Capital Markets Michael Ryskin - Bank of America Joseph Catanzaro - Piper Sandler Chris Shibutani - Goldman Sachs Operator Thank you for standing by. Welcome to Schrödinger's Conference Call to review Second Quarter 2023 Financial Results.

Schrödinger, Inc. (SDGR) Q2 2023 Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. today announced financial results for the quarter ended on June 30, 2023.

Schrödinger Reports Second Quarter 2023 Financial Results

Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users.

Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist

RadNet

But some stocks in the biotech category are rising for a reason that's more common with techs, such as chipmaker Nvidia Corp. NASDAQ: NVDA or Microsoft Corp. NASDAQ: MSFT, which has made a significant investment in OpenAI, developer of ChatGPT.

Biotech & Healthcare Meet AI: Stocks Soar On Innovation Potential

Schrodinger, Inc. (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Schrodinger, Inc. (SDGR) Report Negative Earnings Next Week? What You Should Know

Shares of Recursion Pharmaceuticals, Schrodinger and others that are implementing AI are surging.

News for Schrodinger Stock (SDGR)